#Japan #Tokyo #cancer screening #Salivatech #CRIK Shinanomachi

Salivatech Takes New Steps in Preventive Healthcare

Salivatech, a pioneering company founded by CEO Makoto Sunamura, has officially relocated its Tokyo office to Keio University's CRIK Shinanomachi campus, effective April 2025. This strategic move is aimed at accelerating research and implementation of saliva bio-marker technology to promote preventive healthcare.

What is CRIK Shinanomachi?

CRIK Shinanomachi, or the Center for Research and Incubation at Keio University, is a collaborative research hub designed to foster health and healthcare initiatives rooted in real-world applications. This research facility not only focuses on innovative medical solutions but promotes a collective growth environment where entrepreneurs, researchers, and enterprises from diverse fields come together to bring transformational changes through co-creation.

Located on the 9th floor of the Keio University Medical School and University Hospital in Shinanomachi, the center becomes an epicenter for innovations in the medical field aimed at leveraging research for societal upliftment.

Voices from the Tokyo Office Staff

Employees at Salivatech's Tokyo office expressed enthusiasm about the new location within the university hospital. They noted that having close interactions with esteemed medical professionals enhances their work experience significantly, offering a great opportunity for exchanging ideas with other startups across various disciplines.

As one employee stated, "I have encountered passionate companies at CRIK Shinanomachi and feel deeply impressed by the innovative spirit surrounding this environment. The synergy created through collaboration with academia presents a fascinating potential for research outcomes that can significantly contribute to society. I aspire to maximize my potential while contributing to groundbreaking initiatives in the future."

Saliva Cancer Risk Screening: Salivachecker

Salivatech has developed a saliva cancer risk testing kit named Salivachecker. This innovative kit analyzes the concentration of metabolites in saliva to assess the risk of cancer by identifying abnormal levels of substances typically found in cancer patients. The process is simple and non-invasive—users collect saliva samples at home and send them back to Salivatech for analysis.

The Salivachecker allows for assessing multiple cancer risks in a single test. For men, it analyzes five types of cancers including lung, stomach, colorectal, pancreatic, and oral cancers, while women are additionally screened for breast cancer. Based on the test results, individuals are encouraged to consult with medical professionals for early detection and intervention.

Salivatech’s Mission

Salivatech is dedicated to contributing to early disease detection and intervention through screening testing. As a bridge between self-care and medical treatment, they aim to safeguard people's lives and well-being by offering innovative solutions to society. Collaborative efforts with academia facilitate ongoing technological development and clinical research, ensuring timely access to outcomes that can be beneficially integrated into the community.

Company Overview

• - Company Name: Salivatech Co., Ltd.
• - CEO: Makoto Sunamura
• - Business Areas:

- Saliva-based cancer risk screening
- Development of new risk screening tests
- Contract research testing services

For more information, you can contact Salivatech at:

• - Fax: 0235-26-0588
• - Email: press@salivatech.jp
• - Website: Salivatech